Raltegravir-based HAART regimen in a patient with large B-cell lymphoma

Annals of Pharmacotherapy

Volumn 44, Issue 2, 2010, Pages 377-382

  Fulco, Patricia Pecora ^a   Hynicka, Lauren ^b   Rackley, Dwight ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Abacavir; Antiretroviral therapy; CYP3A4; Diffuse large B cell lymphoma; Drug interactions; Highly active antiretroviral therapy; Integrase inhibitor; Lamivudine; Nonnucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Protease inhibitors; Raltegravir; Tumor lysis syndrome

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATOVAQUONE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HYDROCORTISONE; METHOTREXATE; PREDNISONE; RALTEGRAVIR; VINCRISTINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CD4 LYMPHOCYTE COUNT; DIPLOPIA; DRUG ERUPTION; EYE DISCOMFORT; EYE SWELLING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INGUINAL LYMPH NODE; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; VIRUS LOAD; VOMITING; WEIGHT REDUCTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG INTERACTIONS; HIV INTEGRASE INHIBITORS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; PYRROLIDINONES; VINCRISTINE;

EID: 76149115225     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M370     Document Type: Article

References (36)

1. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008;1-128. www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf (accessed 2008 Nov 4).
2. Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008;22:489-96.
3. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20: 1645-54.
4. Antinori A, Cigolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-91.
5. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus - associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19:2171-8.
6. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005;44:111- 45.
7. Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004;104:2943-6.
8. Product information. Isentress (raltegravir). Whitehouse Station, NJ: Merck, July 2009.
9. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-54.
10. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatmentnaïve patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52:350-6.
11. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatmentnaïve patients with HIV-1 infection: a multicenter, double-blind randomized controlled trial. Lancet 2009;374:796-806.
12. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008;1-127. www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf (accessed 2008 Nov 4).
13. Coiffier B, Altman A, Pui C, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26:2767-78.
14. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006;34:1317-27.
15. Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, Hall SD. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther 2008;327:248-57.
16. Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005;312:83-91.
17. Leveque D, Jehl F. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. J Clin Pharmacol 2007;47:579-88.
18. Correll T, Klibanov OM. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy 2008;28:90-101.
19. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001;29:100-2.
20. Piscitelli SC, Kress DR, Ertz RJ, Pau A, Davey R. The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy 2002;20:549-53.
21. Goeptar AR, Te Koppele JM, Lamme EK, et al. Cytochrome P450 2B1-mediated one-electron reduction of Adriamycin: a study with rat liver microsomes and purified enzymes. Mol Pharmacol 1993;44:1267-77.
22. Goeptar AR, Groot EF, Scheerens H, et al. Cytotoxicity of mitomycin C and Adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450. Cancer Res 1994;54:2411-8.
23. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol 2004;15:1805-9.
24. Makinson A, Martelli N, Peyriere H, Turriere C, Le Moing V, Reynes J. Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol 2007;78:358-60.
25. Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 2006;76:269-71.
26. Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP. Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine. Pharm World Sci 2009; (Sept 10) Epub ahead of print:1-3.
27. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91:155-63.
28. Boue F, Gabarre J, Cisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-8.
29. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 Phase 2 trials. Blood 2005; 105:1891-7.
30. Ribera J-M, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, Adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus - associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008;140:411-9.
31. Spina M, Simonelli C, Tirelli U. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2007;25:e7.
32. Product information. Selzenty (maraviroc). New York, NY: Pfizer, November 2008.
33. Product information. Fuzeon (enfuvirtide). Nutley, NJ: Roche Pharmaceuticals, December 2008.
34. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.
35. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95.
36. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5.